Cyclosporin in the treatment of patients with atopic eczema - A systematic review and meta-analysis

Journal of the European Academy of Dermatology and Venereology

Volumn 21, Issue 5, 2007, Pages 606-619

  Schmitt, Jochen ^a   Schmitt, N ^b   Meurer, M ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Atopic dermatitis; Cyclosporin; Immunosuppression; Meta analysis; Systemic treatment

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; CYCLOSPORIN A; HYDROCORTISONE; PLACEBO; PSORALEN; STEROID; TACROLIMUS;

ABDOMINAL PAIN; ATOPIC DERMATITIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COCHRANE LIBRARY; CONFIDENCE INTERVAL; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; INFECTION; INFORMATION RETRIEVAL; LONG TERM CARE; LOW DRUG DOSE; MEDLINE; META ANALYSIS; NAUSEA; PARESTHESIA; PRIORITY JOURNAL; PUVA; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; THERAPY RESISTANCE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VOMITING;

CYCLOSPORINE; DERMATITIS, ATOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 34250337259     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2006.02023.x     Document Type: Review

References (56)

1. Williams HC. Clinical practice. Atopic dermatitis. N Engl J Med 2005; 352: 2314-2324.
2. Williams H, Robertson C, Stewart A et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. J Allergy Clin Immunol 1999; 103: 125-138.
3. Rystedt I. Long-term follow-up in atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1985; 114: 117-120.
4. Lammintausta K, Kalimo K, Raitala R, Forsten Y. Prognosis of atopic dermatitis. A prospective study in early adulthood. Int J Dermatol 1991; 30: 563-568.
5. Emerson RM, Williams HC, Allen BR. Severity distribution of atopic dermatitis in the community and its relationship to secondary referral. Br J Dermatol 1998; 139: 73-76.
6. Chamlin SL, Frieden IJ, Williams ML, Chren MM. Effects of atopic dermatitis on young American children and their families. Pediatrics 2004; 114: 607-611.
7. Fivenson D, Arnold RJ, Kaniecki DJ et al. The effect of atopic dermatitis on total burden of illness and quality of life on adults and children in a large managed care organization. J Manag Care Pharm 2002; 8: 333-342.
8. Carroll CL, Balkrishnan R, Feldman SR, Fleischer AB Jr, Manuel JC. The burden of atopic dermatitis: Impact on the patient, family, and society. Pediatr Dermatol 2005; 22: 192-199.
9. Kemp AS. Cost of illness of atopic dermatitis in children: A societal perspective. Pharmacoeconomics 2003; 21: 105-113.
10. Dickel H, Bruckner TM, Schmidt A, Diepgen TL. Impact of atopic skin diathesis on occupational skin disease incidence in a working population. J Invest Dermatol 2003; 121: 37-40.
11. Ellis C, Luger T, Abeck D, Allen R et al. International consensus conference on atopic dermatitis II (ICCAD II): Clinical update and current treatment strategies. Br J Dermatol 2003; 148: 3-10.
12. Hanifin JM, Cooper KD, Ho VC et al. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association 'administrative regulations for evidence-based clinical practice guidelines'. J Am Acad Dermatol 2004; 50: 391-404.
13. Borel JF, Feurer C, Gubler HU, Stahelin H. Biological effects of cyclosporin A: A new antilymphocytic agent. Agents Actions 1976; 6: 468-475.
14. Faulds D, Goa KL, Benfield P. Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 1993; 45: 953-1040.
15. Liu J. FK506 and cyclosporin, molecular probes for studying intracellular signal transduction. Immunol Today 1993; 14: 290-295.
16. Curtin F, Elbourne D, Altman DG. Meta-analysis combining parallel and cross-over clinical trials. III: The issue of carry-over. Stat Med 2002; 21: 2161-2173.
17. Elbourne DR, Altman DG, Higgins JP et al. Meta-analyses involving cross-over trials: Methodological issues. Int J Epidemiol 2002; 31: 140-149.
18. Hanifin J, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh) 1980; 92: 44-47.
19. Williams HC, Burney PG, Pembroke AC, Hay RJ. Validation of the U.K. diagnostic criteria for atopic dermatitis in a population setting. U.K. Diagnostic Criteria for Atopic Dermatitis Working Party. Br J Dermatol 1996; 135: 12-17.
20. Stata Corporation. Stata statistical software: Release 8.0. Stata Corporation, College Station, TX, 2002.
21. Stata Corporation. Stata 8 reference manual. College Station, TX, USA 2003.
22. Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta-analysis. Stat Med 2001; 20: 641-654.
23. Harper JI, Ahmed I, Barclay G et al. Cyclosporin for severe childhood atopic dermatitis: Short course versus continuous therapy. Br J Dermatol 2000; 142: 52-58.
24. Berth-Jones J, Graham-Brown RA, Marks R et al. Long-term efficacy and safety of cyclosporin in severe adult atopic dermatitis. Br J Dermatol 1997; 136: 76-81.
25. Berth-Jones J, Finlay AY, Zaki I et al. Cyclosporine in severe childhood atopic dermatitis: A multicenter study. J Am Acad Dermatol 1996; 34: 1016-1021.
26. Czech W, Brautigam M, Weidinger G, Schopf E. A body-weight-independent dosing regimen of cyclosporine microemulsion is effective in severe atopic dermatitis and improves the quality of life. J Am Acad Dermatol 2000; 42: 653-659.
27. Sowden JM, Berth-Jones J, Ross JS et al. Double-blind, controlled, cross-over study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet 1991; 338: 137-140.
28. Zonneveld IM, de Rie MA, Beljaards RC et al. The long-term safety and efficacy of cyclosporin in severe refractory atopic dermatitis: A comparison of two dosage regimens. Br J Dermatol 1996; 135: 15-20.
29. Zurbriggen B, Wuthrich B, Cachelin AB, Wili PB, Kagi MK. Comparison of two formulations of cyclosporin A in the treatment of severe atopic dermatitis. A double-blind, single-centre, cross-over pilot study. Dermatology 1999; 198: 56-60.
30. Munro CS, Levell NJ, Shuster S, Friedmann PS. Maintenance treatment with cyclosporin in atopic eczema. Br J Dermatol 1994; 130: 376-380.
31. Bunikowski R, Staab D, Kussebi F et al. Low-dose cyclosporin A microemulsion in children with severe atopic dermatitis: Clinical and immunological effects. Pediatr Allergy Immunol 2001; 12: 216-223.
32. Granlund H, Erkko P, Sinisalo M, Reitamo S. Cyclosporin in atopic dermatitis: Time to relapse and effect of intermittent therapy. Br J Dermatol 1995; 132: 106-112.
33. van Joost T, Heule F, Korstanje M et al. Cyclosporin in atopic dermatitis: A multicentre placebo-controlled study. Br J Dermatol 1994; 130: 634-640.
34. Pacor ML, Di Lorenzo G, Martinelli N et al. Comparing tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis: A randomized study. Clin Exp Allergy 2004; 34: 639-645.
35. Pacor ML, Biasi D, Di Lorenzo G, Carletto A, Corrocher R. Cyclosporin in atopic dermatitis. Recenti Prog Med 2001; 92: 390-391.
36. Caproni M, Salvatore E, Cardinali C, Brazzini B, Fabbri P. Soluble CD30 and cyclosporine in severe atopic dermatitis. Int Arch Allergy Immunol 2000; 121: 324-328.
37. Atakan N, Erdem C. The efficacy, tolerability and safety of a new oral formulation of Sandimmun®-Sandimmun Neoral® in severe refractory atopic dermatitis. J Eur Acad Dermatol Venereol 1998; 11: 240-246.
38. Charman C, Williams H. Outcome measures of disease severity in atopic eczema. Arch Dermatol 2000; 136: 763-769.
39. Chren MM. Giving 'scale' new meaning in dermatology: Measurement matters. Arch Dermatol 2000; 136: 788-790.
40. Costa C, Rilliet A, Nicolet M, Saurat JH. Scoring atopic dermatitis: The simpler the better? Acta Derm Venereol 1989; 69: 41-45.
41. Severity scoring of atopic dermatitis: The SCORAD index. Consensus report of the European task force on atopic dermatitis. Dermatology 1993; 186: 23-31.
42. Berth-Jones J. Six-area, six-sign atopic dermatitis (SASSAD) severity score: A simple system for monitoring disease activity in atopic dermatitis. Br J Dermatol 1996; 135: 25-30.
43. Szklo M, Nieto J. Epidemiology Beyond the Basics. Jones and Barlett Publishers, Sidbury, MA, 2005: 205-208.
44. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.
45. Lewis V, Finlay AY. 10 years experience of the dermatology life quality index (DLQI). J Invest Dermatol Symp Proc 2004; 9: 169-180.
46. Lewis-Jones MS, Finlay AY. The children's dermatology life quality index (CDLQI): Initial validation and practical use. Br J Dermatol 1995; 132: 942-949.
47. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 1987; 9: 1-30.
48. Marcil I, Stern RS. Squamous cell cancer of the skin in patients given PUVA and cyclosporin: Nested cohort cross-over study. Lancet 2001; 358: 1042-1045.
49. Behnam SM, Behnam SE, Koo JY. Review of cyclosporine immunosuppressive safety data in dermatology patients after two decades of use. J Drugs Dermatol 2005; 4: 189-194.
50. Kirby B, Owen CM, Blewitt RW, Yates VM. Cutaneous T-cell lymphoma developing in a patient on cyclosporin therapy. J Am Acad Dermatol 2002; 47: S165-S167.
51. Fletcher CL, Orchard GE, Hubbard V et al. CD30(+) cutaneous lymphoma in association with atopic eczema. Arch Dermatol 2004; 140: 449-454.
52. Laube S, Stephens M, Smith AG, Whittaker SJ, Tan BB. Lymphomatoid papulosis in a patient with atopic eczema on long-term cyclosporin therapy. Br J Dermatol 2005; 152: 1346-1348.
53. Sinha A, Velangi S, Natarajan S. Non-Hodgkin's lymphoma following treatment of atopic eczema with cyclosporin A. Acta Derm Venereol 2004; 84: 327-328.
54. Koo JY, Kadonaga JN, Wintroub BV, Lozada-Nur FI. The development of B-cell lymphoma in a patient with psoriasis treated with cyclosporine. J Am Acad Dermatol 1992; 26: 836-840.
55. Corazza M, Zampino MR, Montanari A, Altieri E, Virgili A. Primary cutaneous CD30+ large T-cell lymphoma in a patient with psoriasis treated with cyclosporine. Dermatology 2003; 206: 330-333.
56. Finlay AY. Quality of life in atopic dermatitis. J Am Acad Dermatol 2001; 45: S64-S66.